

Portland State University

**PDXScholar**

---

OHSU-PSU School of Public Health Faculty  
Publications and Presentations

OHSU-PSU School of Public Health

---

11-2017

# Frequency of Cannabis Use among Primary Care Patients in Washington State

Gwen T. Lapham

*Kaiser Permanente Washington Health Research Institute*

Amy K. Lee

*Kaiser Permanente Washington Health Research Institute*

Ryan M. Caldeiro

*Kaiser Foundation Health Plan of Washington*

Dennis McCarty

*Oregon Health & Science University*

Kendall C. Browne

*VA Puget Sound Health Care System*

*See next page for additional authors*

Follow this and additional works at: [https://pdxscholar.library.pdx.edu/sph\\_facpub](https://pdxscholar.library.pdx.edu/sph_facpub)



Part of the [Primary Care Commons](#)

**Let us know how access to this document benefits you.**

---

## Citation Details

Lapham, G. T., Lee, A. K., Caldeiro, R. M., McCarty, D., Browne, K. C., Walker, D. D., ... & Bradley, K. A. (2017). Frequency of Cannabis Use Among Primary Care Patients in Washington State. *The Journal of the American Board of Family Medicine*, 30(6), 795-805.

This Post-Print is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School of Public Health Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [pdxscholar@pdx.edu](mailto:pdxscholar@pdx.edu).

---

**Authors**

Gwen T. Lapham, Amy K. Lee, Ryan M. Caldeiro, Dennis McCarty, Kendall C. Browne, Denise D. Walker, Daniel R. Kivlahan, and Katharine A. Bradley

Published in final edited form as:

*J Am Board Fam Med.* 2017 ; 30(6): 795–805. doi:10.3122/jabfm.2017.06.170062.

## Frequency of Cannabis Use among Primary Care Patients in Washington State

Gwen T. Lapham, PhD, MPH MSW<sup>1</sup>, Amy K. Lee, MPH<sup>1</sup>, Ryan M. Caldeiro, MD<sup>2</sup>, Dennis McCarty, PhD<sup>3</sup>, Kendall C. Browne, PhD<sup>4,5</sup>, Denise D. Walker, PhD<sup>6</sup>, Daniel R. Kivlahan, PhD<sup>5,6,7</sup>, and Katharine A. Bradley, MD, MPH<sup>1,8,9</sup>

<sup>1</sup>Kaiser Permanente Washington Health Research Institute

<sup>2</sup>Behavioral Health Support Services, Kaiser Foundation Health Plan of Washington

<sup>3</sup>Oregon Health & Science University (OHSU) - Portland State University School of Public Health, OHSU

<sup>4</sup>Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System

<sup>5</sup>Department of Psychiatry and Behavioral Sciences, University of Washington

<sup>6</sup>Innovative Programs Research Group, School of Social Work, University of Washington

<sup>7</sup>Health Services Research & Development VA Puget Sound Health Care System, Center of Innovation for Veteran-Centered Value-Driven Care

<sup>8</sup>Department of Health Services, University of Washington

<sup>9</sup>Department of Medicine, University of Washington

### Abstract

**Background and Objectives**—Over 12% of U.S. adults report past-year cannabis use, and among those who use daily, 25% or more have a cannabis use disorder. Use is increasing as legal access expands. Yet, cannabis use is not routinely assessed in primary care, and little is known about use among primary care patients and relevant demographic and behavioral health subgroups. This study describes the prevalence and frequency of past-year cannabis use among primary care patients assessed for use during a primary care visit.

**Methods**—This observational cohort study included adults who made a visit to primary care clinics with annual behavioral health screening, including a single-item question about frequency past-year cannabis use (March 2015-February 2016; n=29,857). Depression, alcohol and other drug use were also assessed by behavioral health screening. Screening results, tobacco use, and diagnoses for past-year behavioral health conditions (e.g., mental health and substance use disorders) were obtained from EHRs.

---

Corresponding Author: Gwen Lapham, PhD, MPH, MSW, Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, Phone: 206-287-2021, lapham.g@ghc.org.

#### **CONFLICT OF INTEREST DISCLOSURES**

Dr. McCarty was the principal investigator on research service agreements with Purdue Pharma and Alkermes. No other disclosures to report.

**Results**—Among patients who completed the cannabis use question (n=22,095; 74% of eligible patients), 15.3% (14.8–15.8%) reported any past-year use: 12.2% (11.8%–12.6%) less than daily and 3.1% (2.9%–3.3%) daily. Among 2,228 patients 18–29 years, 36.0% (34.0%–38.0%) reported any cannabis use and 8.1% (7.0%–9.3%) daily use. Daily cannabis use was common among men 18–29 who used tobacco or screened positive for depression: 25.5% (18.8%–32.1%) and 31.7% (23.3%–40.0%), respectively.

**Conclusions**—Cannabis use was common in adult primary care patients, especially among younger patients and those with behavioral health conditions. Results highlight the need for primary care approaches to address cannabis use.

## Keywords

Primary health care; screening; Cannabis

---

## INTRODUCTION

Cannabis is the most commonly used drug in the United States, after alcohol and tobacco.<sup>1</sup> As of 2013, 13% of U.S. adults – nearly 20 million people - used cannabis in the past year, and over 8 million used daily.<sup>1</sup> Nearly 3 in 10 adults who use cannabis have a cannabis use disorder, defined as meeting 2 or more of 11 substance use disorder criteria (Table 1).<sup>2,3</sup> The prevalence of a cannabis use disorder increases with increasing frequency of use.<sup>1,3,4</sup>

With expanding legalization of cannabis use, the number of cannabis users—and daily cannabis users at greatest risk for a cannabis use disorder<sup>4</sup>—is projected to grow over the next 5–10 years.<sup>5</sup> Medical cannabis use is now legal in 29 states and nonmedical use in 8, including California, and the District of Columbia, with more states considering legalization.<sup>6,7</sup> Sale of cannabis for nonmedical use, including dried plant materials and increasingly, a wide variety of highly-potent cannabinoid products, began in 2014 in Colorado and Washington State, with restricted start-up sales beginning in 2015 for Oregon and in 2016 for Alaska.<sup>8,9</sup> Yet, to our knowledge, cannabis use is not routinely assessed in U.S. primary care settings. As cannabis use increases, primary care providers may want to know when patients use cannabis regularly.<sup>10</sup>

No U.S. study has evaluated the population-based prevalence of patient-reported cannabis use among primary care patients, particularly in a state where nonmedical use is legal. Kaiser Permanente Washington (formerly Group Health), an integrated health system in Washington State, is currently implementing routine behavioral health screening as part of behavioral health integration in primary care clinics. At the request of providers, in the context of state legalization, a question about cannabis use was added to the behavioral health screen before a question about illicit drug use.<sup>11</sup> The purpose of this study was to assess the prevalence and frequency of self-reported past-year cannabis use among primary care patients. Specifically, the prevalence and frequency of cannabis use is described in the total primary care sample, as well as within demographic and behavioral health subgroups. The study also addresses implications for primary care for patients who use cannabis.

## METHODS

### Setting

Kaiser Permanente Washington, a nonprofit health care system with 25 primary care sites throughout Washington State, implemented annual behavioral health screening, including a question about cannabis use, for adults in 3 primary care sites starting in March 2015. Implementation of behavioral health screening was staggered across the three sites, which were chosen for their receptivity to implementation and community representativeness. The sites, spread across 90 miles in Western Washington, enrolled about 80,000 patients (17,000 – 37,000 per clinic). Site A initiated behavioral health screening in March 2015 (2 of 3 primary care clinics within the site); Site B initiated in early October (2 of 4 clinics); and Site C initiated in late October in (1 of 2 clinics). Staff at each site assisted with work flow development for behavioral health screening and met regularly to review and improve screening prevalence (target 80%). Electronic health record (EHR) prompts alerted staff when patients were due for screening. After check-in, patients completed a 7-item behavioral health screen (described below) on paper. Medical assistants typically entered results into the EHR and shared the results with the provider prior to the patient-provider visit.

### Data Source and Study Population

This observational cohort study obtained study data, including behavioral health screen results and patient demographic and clinical characteristics, from Kaiser Permanente Washington's EHR. Patients 18 years and older were included if they attended an in-person visit with a primary care provider in one of the 3 participating primary care sites from study start (i.e., after initiation of screening at each site) through mid-February 2016. Patients with EHR documentation of a response to the cannabis question during the study period, indicating question completion, comprised the study sample. This study received approval and waivers of consent and HIPAA authorization from the Kaiser Permanente Washington Health Research Institute Institutional Review Board.

### Measures

#### The 7-item Behavioral Health Screen

**Past-Year Cannabis Use:** The single-item cannabis use question, modeled after the third question of the World Health Organization's (WHO) 10-item AUDIT,<sup>12</sup> asked about the frequency of past-year cannabis use (i.e., "How often in the past year did you use marijuana?" - "never", "less than monthly", "monthly", "weekly", and "daily or almost daily"). The response options are identical to the second question of the WHO ASSIST questionnaire.<sup>13</sup> A categorical variable for the *frequency of past-year cannabis use* was defined as none ("never"), less than daily ("less than monthly", "monthly" and "weekly") and daily ("daily or almost daily"). Any response other than 'never' was considered positive for *any past-year cannabis use*. The term 'marijuana' was used in the question as it is the most commonly used U.S. cannabis term.<sup>14</sup> Marijuana use was not defined and could include nonmedical and medical use.

**Additional Behavioral Health Screen items:** The 7-item screen also included the 2-item Patient Health Questionnaire (PHQ-2) to assess possible depression in the past two weeks (item scores 0–3; scores of 2 or 3 were positive for *depression*)<sup>15</sup> and the 3-item Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) questionnaire to assess unhealthy alcohol use in the past year (total scores of 3 for women and 4 for men were positive for *unhealthy alcohol use*).<sup>16</sup> A single-item screen for frequency of past-year illicit drug use or nonmedical use of prescription medication, which followed the cannabis screen, was adapted from a validated screen<sup>11</sup> and had response options identical to the cannabis screen, with any response other than ‘never’ positive for *past-year illicit drug use/medication misuse*. In the uncommon case that a patient completed the 7-item screen more than once during the study period (2.4% of patients), the highest score for each condition-specific screen, if different, was used.

**Demographic and Other Behavioral Health Conditions—**Gender (women/men), age (18–29, 30–49, 50–64, 65), race/ethnicity (black, Hispanic, other, white, unknown)<sup>17</sup> were extracted from the EHR at the time of each patient’s initial in-person visit to the sites during the study period. Behavioral health characteristics were selected based on their association with cannabis use. Current *tobacco use* was based on any EHR documentation in the year prior to initial visit that the patient reported currently using tobacco. Diagnostic codes based on ICD-9-CM (prior to October 1, 2015) and ICD-10-CM (as of October 1, 2015) documentation in the EHR by providers for conditions addressed or considered during an encounter were used to classify mental health and substance use disorders recognized in the year prior to the cannabis screen. Mental health disorders in the past year were categorized into *major depressive disorders*, *anxiety disorders*, including generalized anxiety, panic, phobias and PTSD, and *serious mental illness*, including schizophrenia, bipolar disorder and psychosis. Substance use disorders in the past year were categorized into *alcohol use disorders*, *cannabis use disorders* and *other drug use disorders* (i.e., does not include nicotine, alcohol or cannabis). Consistent with the use of the cannabis use question as routine clinical assessment of the frequency of use (i.e., not as a diagnostic tool for a disorder), patients with a cannabis use disorder were included in the study. Composite indicators for *any mental health disorder* (e.g., depression, anxiety, serious mental illness) and *any non-cannabis substance use disorder* (e.g., alcohol and other drug use disorders) were also evaluated.

## Analyses

Analyses described sample characteristics, including the prevalence and frequency of past-year cannabis use. The prevalence and frequency of past-year cannabis use, along with 95% confidence intervals, were also calculated among patient subgroups based on demographic (e.g., patients within each category of gender, age, and race/ethnicity) and behavioral health (e.g., patients who screened positive on a behavioral health screen or had documentation of a behavioral health condition/diagnosis) characteristics.<sup>1</sup> All analyses were conducted in Stata Version 13.1 MP edition.

## RESULTS

A total of 29,857 patients visited the 3 primary care sites during the study period, and of those, 22,095 (74.0%) patients had EHR documentation of the question about past-year cannabis use and were included in the study sample. Among patients who made a visit, those who completed the cannabis use question were similar to those who did not (data available upon request).

Most patients in the study sample were female, white and older; 9.7% reported current tobacco use and 15.0% had a major depression diagnosis in the past year [Table 2]. Among patients in the sample, 15.3% (95% CI 14.8%–15.8%) reported any cannabis use in the past year: 7.7% (7.3%–8.0%) less than monthly; 2.2% (2.0%–2.4%) monthly; 2.3% (2.1%–2.5%) weekly; and 3.1% (2.9%–3.3%) daily. Among those who reported any cannabis use, 50.1% (48.4%–51.8%) reported infrequent use (<monthly), 14.6% (13.5%–15.9%) and 15.0% (13.8%–16.2%) reported monthly and weekly use, respectively, and 20.3% (19.0%–21.7%) reported daily use.

The prevalence and frequency of past-year cannabis use was high among men and patients 18–29 years old [Figure 1 Panel A]. In particular, 32.1% (29.7%–34.5%) of women 18–29 years reported any cannabis use and 6.1% (4.9%–7.4%) reported daily use, while 43.6% (40.1%–47.2%) of men 18–29 years reported any cannabis use and 12.1% (9.7%–14.4%) daily use.

Compared to the prevalence among all primary care patients, any and daily past-year cannabis use was higher among patients in each behavioral health subgroup [Figure 1 Panel B]. Among 5,340 patients with a mental health disorder, 18.9% (17.9%–20.0%) and 4.5% (3.9%–5.0%) reported any and daily past-year cannabis use, respectively, while among 558 patients with a non-cannabis substance use disorder, 31.0% (27.3%–35.0%) and 8.4% (6.4%–11.0%) reported any and daily past-year cannabis use, respectively. Among 109 patients with a cannabis use disorder documented in the past year, 84.4% (76.3%–90.1%) and 49.5% (40.2%–58.9%) reported any and daily past-year use, respectively.

When patient characteristics were combined, the prevalence of cannabis use was higher in some groups [Table 3; Appendix A]. For example, among men 18–29 years who screened positive for depression or reported tobacco use, 63.0% (55.6%–70.4%) and 65.8% (57.3%–74.4%), respectively, reported any cannabis use, with 25.5% (18.8%–32.1%) and 31.7% (23.3%–40.0%), respectively, reporting daily use.

To identify patient characteristics independently associated with increased odds of past-year cannabis use, two post-hoc logistic regressions, with binary outcomes for any use and daily use, were performed and adjusted for all measured patient demographic and clinical characteristics.<sup>18</sup> The adjusted odds of any use were higher among patients who were male, younger, current tobacco users, or had depression, anxiety, unhealthy alcohol use, or illicit drug use/prescription medication misuse, with similar results for daily use (Table 4). Patients 18–29 years had the highest adjusted odds of any use and daily use, 7.34 (6.42–8.40) and 4.82 (3.67–6.31), respectively, when compared to patients 65 years and older.

## DISCUSSION

More than 1 in 6 primary care patients in a state where cannabis use is legal reported using cannabis when screened for depression, unhealthy alcohol use, cannabis and illicit drug use as part of routine behavioral health screening. Cannabis use was particularly common among young adults—nearly 4 in 10 reported past-year use—and among those with tobacco use, unhealthy alcohol use, illicit drug use, or mental health or substance use disorders. Daily cannabis use was reported by 1 in 12 young adults and nearly 1 in 20 patients with a mental health disorder. However, when multiple characteristics associated with use were combined (e.g. young men who used tobacco or screened positive for depression), the prevalence of daily use exceeded 25%. These relationships persisted after adjustment, with younger patients and those with other substance use and behavioral health concerns having higher adjusted odds of any and daily cannabis use.

As states legalize use of cannabis, the perception that cannabis use is safe has increased.<sup>19,20</sup> However, frequent and/or high-potency cannabis use—irrespective of the purpose—increases the risk of cannabis use disorder. Moreover, the concentration of tetrahydrocannabinol (THC), the main psychoactive and addictive component in cannabis, has increased in cannabis plants from an average of 3% to 12% in recent years, with some in excess of 20%, contributing to a higher prevalence of cannabis use disorders.<sup>21</sup> New methods of administration and new products, including concentrated hash oil, synthetic cannabinoids and edibles, have further increased the per-use potency of cannabis and the risk of addiction.<sup>22,23</sup> More than 9% of lifetime cannabis users will develop and 25%–50% patients who use daily are at risk for a cannabis use disorder.<sup>3,24,25</sup> Young adults have the greatest risk, with 35% of current users meeting criteria for a cannabis use disorder.<sup>26</sup> Young adults may also be most adversely impacted, as frequent use diminishes educational, occupational, cognitive and social development.<sup>27,28</sup> Patients who use cannabis for medical purposes, the majority of whom also use recreationally, are more likely to use multiples times per day and to use highly potent forms of cannabis to manage symptoms.<sup>8</sup> All of these factors increase the risk that patients who use cannabis will develop a cannabis use disorder.

Cannabis use poses other significant health risks, which increase with the frequency and intensity of use: 1) central nervous system impairment, acute (e.g., judgment, coordination) and chronic (e.g., memory, cognition),<sup>29</sup> 2) exacerbation and persistence of psychiatric symptoms (e.g., depression, psychosis),<sup>30</sup> 3) development of other drug use disorders, including nicotine and alcohol<sup>31</sup> 4) prescription medication interactions (e.g., antidepressants, opioids),<sup>32</sup> 5) prenatal exposure during pregnancy,<sup>33</sup> 6) pulmonary symptoms<sup>29</sup> and 7) accidents, particularly motor vehicle accidents.<sup>34</sup> Finally, frequent use of cannabis can cause significant withdrawal, which appears clinically similar to tobacco and opioid withdrawal, with symptoms of anxiety, irritability, depressed mood, disturbed sleep, decreased appetite and restlessness.<sup>35</sup>

Although cannabis use has established health risks, the U.S. Preventive Services Task Force does not currently recommend routine preventive screening for cannabis or other illicit drug use in primary care due to the lack of known effective brief primary care interventions to decrease drug use.<sup>36</sup> However, the value of asking about cannabis use, separate from brief



interventions, has not been investigated. Results of this study suggest primary care patients are willing to report cannabis use, including daily use, as part of behavioral health screening documented in their EHRs.

Knowledge of patients' cannabis use could help providers initiate conversations with patients, allowing for assessment of the reasons, perceived risks/benefits, and intensity of cannabis use. While cannabis may have therapeutic value for promoting appetite and treating nausea, spasticity, chronic pain, and neuropathic pain, providers may want to advise patients about more effective and/or safer treatment alternatives available for most conditions.<sup>27,37</sup> Additionally, there is inadequate evidence for the efficacy of cannabis use for some conditions/symptoms, like depression and anxiety, which can be worsened by cannabis use.<sup>38</sup> Because of the potential for harm, women should be advised against cannabis use during pregnancy.<sup>39</sup>

For patients who use cannabis regularly, assessment of the intensity (e.g., frequency per-day, method of administration) and potency of use, as well as symptoms of a cannabis use disorder using questionnaires like the Cannabis Use Disorders Identification Test<sup>40</sup> or DSM-5 substance use disorder criteria,<sup>41</sup> can provide additional information about a patient's risk for cannabis-related consequences, including addiction. For patients who have a cannabis use disorder, cognitive behavioral and motivational enhancement therapies are effective, separately and in combination, in reducing cannabis use and the severity of disorder symptoms.<sup>42,43</sup> Contingency management can augment treatment outcomes when paired with these therapies.<sup>42,43</sup> No medication has proven broadly effective nor been approved for treatment of cannabis use disorders.<sup>42</sup> Most pharmacotherapies evaluated, including antidepressants, bupropion, buspirone, and atomoxetine, have shown little value in treating cannabis use disorders.<sup>44</sup> Although gabapentin, N-acetylcysteine (NAC), especially NAC for 18–21 year olds,<sup>45</sup> and medications containing THC have shown promise, further investigation is needed. As most patients with a cannabis use disorder will not seek care in formal treatment settings,<sup>1,46</sup> behavioral and other effective treatments for cannabis use disorders in primary care are needed.

There are several limitations to this study. Although the question about cannabis use was adapted from well-validated alcohol and substance use measures, it has not been validated against a gold-standard interview for cannabis use. However, the question has high face validity, and underreporting is expected,<sup>47</sup> making estimates of the prevalence of any cannabis use in this study (15%) conservative. The prevalence of cannabis use in this study is higher than the national prevalence (12.5%),<sup>1</sup> consistent with findings that the prevalence of use is higher in states with legalized use.<sup>48</sup> Furthermore, the frequency of cannabis use among young adults in this sample of Washington State primary care patients is comparable to that reported by young adults in the same state on a 2014 confidential internet-based survey.<sup>19</sup> Although there was no evidence of selective non-response, a quarter of eligible patients did not complete behavioral health screening. Reasons included that medical assistants did not offer the screen (e.g., were busy or staffing was low), patients did not speak/read English, or the primary care provider was behind schedule. The prevalence of cannabis and other substance use disorders in this study, based on documentation by clinicians in the EHR in the previous year, was low compared to US population

estimates,<sup>26,49</sup> in contrast to rates for mental health diagnoses,<sup>50</sup> suggesting under-recognition of substance use disorders. Research is needed to determine whether routine assessment of cannabis and other drug use as part of behavioral health screening increases the prevalence of recognized substance use disorders. Although a question about frequency of past-year cannabis use was practical for routine screening, the question omitted relevant dimensions of use (e.g., potency, frequency per-day, medical vs. nonmedical use). Future studies of cannabis use among primary care patients need to assess differences in medical and nonmedical use and the intensity, potency and methods of cannabis used. Finally, this study was restricted to adults and similar research is needed on younger patients.

In summary, this study of the prevalence and frequency of cannabis use among primary care patients, in a state with legalized use, found that most primary care patients who completed recommended routine behavioral health screening (e.g., depression and alcohol),<sup>51,52</sup> also completed a question about past-year cannabis use. Additionally, while 15% of all primary care patients reported any past-year cannabis use, the prevalence was much higher in important patient subgroups. Most notably, more than 1 in 4 younger men who used tobacco or screened positive for depression reported high-risk *daily* cannabis use. Routinely asking about cannabis use could promote recognition of patients who may benefit from primary care discussions about their cannabis use.

## Acknowledgments

**Author Contributions:** Dr. Lapham had full access to all the study data and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Lapham, Bradley. *Statistical analysis:* Lapham. *Interpretation of results:* All authors. *Drafting of manuscript:* Lapham, Bradley. *Critical revision of the manuscript for important intellectual content:* All authors.

**Funding/Support:** Awards from the National Institute on Drug Abuse (UG1DA040314-01S1, UG1 DA01581) and the Agency for Healthcare Research and Quality (R18 HS023173) supported study implementation, analysis and manuscript preparation.

**Role of the Sponsor:** The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Prior Presentations:** This paper has not been presented at any conference.

## References

1. National Survey on Drug Use and Health (NSDUH). [Accessed October 1, 2015] Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables. 2015. <http://archive.samhsa.gov/data/NSDUH/2013SummNatFindDetTables/Index.aspx>
2. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. *Am J Psychiatry*. 2013; 170(8):834–851. [PubMed: 23903334]
3. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. *JAMA Psychiatry*. 2015; 72(12):1235–1242. [PubMed: 26502112]
4. Moss HB, Chen CM, Yi HY. Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. *J Stud Alcohol Drugs*. 2012; 73(5):820–828. [PubMed: 22846246]
5. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. *Clin Pharmacol Ther*. 2015; 97(6):607–615. [PubMed: 25777798]

6. Prescription Drug Abuse Policy System. [Accessed March 30, 2016] Medical Marijuana Laws for Patients. 2016. Available from: <http://www.pdaps.org/dataset/overview/medical-marijuana-patient-related-laws/56e5ad5bd42e0723743aa700>
7. Pew Research Center. [Accessed November 30, 2015] Majority Now Supports Legalizing Marijuana. 2013. <http://www.people-press.org/2013/04/04/majority-now-supports-legalizing-marijuana/>
8. Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. *Addiction*. 2016; 111(6):973–980. [PubMed: 26687431]
9. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products. *JAMA*. 2015; 313(24):2491–2493. [PubMed: 26103034]
10. Kleiman, M. A Cannabis Research Agenda for Policy Design: What do we need to know?. Paper presented at: Marijuana and Cannabinoids: A Neuroscience Research Summit; 2016; Bethesda, MD.
11. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. *Arch Intern Med*. 2010; 170(13):1155–1160. [PubMed: 20625025]
12. Babor, TF., Higgins-Biddle, JC., Saunders, JB., Monteiro, MG. [Accessed Feb 1, 2012] AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. 22001. <http://www.dass.stir.ac.uk/DRUGS/pdf/audit.pdf>
13. WHO Assist Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. *Addiction*. 2002; 97(9):1183–1194. [PubMed: 12199834]
14. Ruschmann, P. *Legalizing Marijuana*. New York, NY: Chelsea House; 2004.
15. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care*. 2003; 41(11):1284–1292. [PubMed: 14583691]
16. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007; 31(7):1208–1217. [PubMed: 17451397]
17. Williams EC, Lapham GT, Hawkins EJ, et al. Variation in documented care for unhealthy alcohol consumption across race/ethnicity in the Department of Veterans Affairs Healthcare System. *Alcohol Clin Exp Res*. 2012; 36(9):1614–1622. [PubMed: 22404130]
18. Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. *Am J Epidemiol*. 2008; 168(1):89–97. [PubMed: 18477651]
19. Center for the Study of Health and Risk Behaviors, University of Washington. [Accessed May 3, 2016] Young Adult Health Survey: Marijuana. 2015. Available from: <http://learnaboutmarijuanawa.org/factsheets/YAHS%20Marijuana.pdf>
20. Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. *Drug Alcohol Depend*. 2015; 149:232–244. [PubMed: 25735467]
21. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. *Int J Drug Policy*. 2014; 25(2):308–319. [PubMed: 24502887]
22. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? *Addict Behav*. 2014; 39(10):1430–1433. [PubMed: 24930049]
23. Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ. Online survey characterizing vaporizer use among cannabis users. *Drug Alcohol Depend*. 2016; 159:227–233. [PubMed: 26774946]
24. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. *Psychol Med*. 2006; 36(10):1447–1460. [PubMed: 16854249]
25. Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ. Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. *Drug Alcohol Depend*. 2014; 136:158–161. [PubMed: 24440049]

26. Hasin DS, Kerridge BT, Saha TD, et al. Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Am J Psychiatry*. 2016; 173(6):588–599. [PubMed: 26940807]
27. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med*. 2014; 370(23):2219–2227. [PubMed: 24897085]
28. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. *Psychol Addict Behav*. 2012; 26(3):496–506. [PubMed: 22103843]
29. Schrot RJ, Hubbard JR. Cannabinoids: Medical implications. *Ann Med*. 2016; 48(3):128–141. [PubMed: 26912385]
30. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007; 370(9584):319–328. [PubMed: 17662880]
31. Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. *JAMA Psychiatry*. 2016; 73(4):388–395. [PubMed: 26886046]
32. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. *Curr Opin Pharmacol*. 2010; 10(1):80–86. [PubMed: 19857996]
33. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. *BMJ Open*. 2016; 6(4):e009986.
34. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. *Addiction*. 2016; 111(8):1348–1359. [PubMed: 26878835]
35. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. *Drug Alcohol Depend*. 2011; 119(1–2):123–129. [PubMed: 21724338]
36. Polen, MR., Whitlock, EP., Wisdom, JP., Nygren, P., Bougatsos, C. Screening in Primary Care Settings for Illicit Drug Use: Staged Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: AHRQ; Jan. 2008
37. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *JAMA*. 2015; 313(24):2474–2483. [PubMed: 26103031]
38. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA*. 2015; 313(24):2456–2473. [PubMed: 26103030]
39. Volkow ND, Compton WM, Wargo EM. The Risks of Marijuana Use During Pregnancy. *JAMA*. 2017; 317(2):129–130. [PubMed: 27992628]
40. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). *Drug Alcohol Depend*. 2010; 110(1–2):137–143. [PubMed: 20347232]
41. Saha TD, Compton WM, Chou SP, et al. Analyses related to the development of DSM-5 criteria for substance use related disorders: 1. Toward amphetamine, cocaine and prescription drug use disorder continua using Item Response Theory. *Drug Alcohol Depend*. 2012; 122(1–2):38–46. [PubMed: 21963414]
42. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. *Psychiatr Clin North Am*. 2012; 35(2):309–326. [PubMed: 22640758]
43. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. *Cochrane Database Syst Rev*. 2016; 5(5):CD005336.
44. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. *Cochrane Database Syst Rev*. 2014; 12(12):CD008940.
45. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. *Am J Psychiatry*. 2012; 169(8):805–812. [PubMed: 22706327]
46. McLellan AT. Public accountability in addiction treatment. *Lancet*. 2009; 374(9697):1220–1221. [PubMed: 19819374]
47. Korthuis, PT., Burdick, T., Leed, R., Payment, M., Kunkel, LE., McCarty, D. Using An Electronic Health Record Communication Tool To Assess Patient Attitudes Toward Cannabis Use. Paper presented at: American Society of Addiction Medicine Annual Conference; 2016; Baltimore, MD.

48. Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. *Drug Alcohol Depend.* 2012; 120(1–3):22–27. [PubMed: 22099393]
49. Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. *JAMA Psychiatry.* 2016; 73(1):39–47. [PubMed: 26580136]
50. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med.* 2007; 146(5):317–325. [PubMed: 17339617]
51. U S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. *Ann Intern Med.* 2004; 140(7):554–556. [PubMed: 15068984]
52. U S. Preventive Services Task Force. Screening for depression in adults: U.S. preventive services task force recommendation statement. *Ann Intern Med.* 2009; 151(11):784–792. [PubMed: 19949144]


## **Appendix A. The prevalence and frequency of past-year cannabis use among patient demographic and behavioral health subgroups**

		----- Conditions/Diagnoses in prior year -----				----- Behavioral Health Screens -----												
		Anxiety		Serious Mental Illness		Alcohol use disorder		Other drug use disorder		Depression (PHQ2)		Unhealthy alcohol use		Illicit drug use/Rx misuse				
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI				
----- Age 30-49 years -----																		
Women																		
	(n 371)	(n 554)	(n 634)	(n 123)	(n 48)	(n 32)	(n 527)	(n 881)	(n 48)									
Any use	29.9	(25.3-34.6)	21.8	(18.4-25.3)	22.2	(19.0-25.5)	30.1	(21.9-38.2)	25.0	(12.6-37.4)	34.4	(17.7-51.1)	28.5	(24.6-32.3)	28.6	(25.6-31.6)	47.9	(33.6-62.2)
Frequency of use																		
None	70.1	(65.4-74.8)	78.2	(74.7-81.6)	77.8	(74.5-81.0)	69.9	(61.8-78.1)	75.0	(62.6-87.4)	65.6	(48.9-82.4)	71.5	(67.7-75.4)	71.4	(68.4-74.4)	52.1	(37.8-66.4)
> Daily	19.7	(15.6-23.7)	17.0	(13.8-20.1)	16.4	(13.5-19.3)	22.8	(15.3-30.2)	18.8	(7.6-29.9)	28.1	(12.3-44.0)	19.5	(16.2-22.9)	25.0	(22.1-27.8)	37.5	(23.7-51.4)
Daily	10.2	(7.2-13.3)	4.9	(3.1-6.7)	5.8	(4.0-7.7)	7.3	(2.7-11.9)	6.3	(-0.7-13.2)	6.3	(-2.3-14.8)	8.9	(6.5-11.4)	3.6	(2.4-4.9)	10.4	(1.7-9.2)
----- Age 50 years -----																		
Men																		
	(n 323)	(n 05)	(n 233)	(n 52)	(n 54)	(n 33)	(n 335)	(n 609)	(n 39)									
Any use	36.5	(31.3-41.8)	33.7	(27.2-40.2)	28.8	(22.9-34.6)	36.5	(23.3-49.8)	38.9	(25.8-52.0)	45.5	(28.2-62.7)	37.6	(32.4-42.8)	38.6	(34.7-42.5)	71.8	(57.5-86.1)
Frequency of use																		
None	63.5	(58.2-68.7)	66.3	(59.9-72.8)	71.2	(65.4-77.1)	63.5	(50.2-76.7)	61.1	(48.0-74.2)	54.6	(37.3-71.8)	62.4	(57.2-67.6)	61.4	(57.5-65.3)	28.2	(13.9-42.5)
> Daily	24.8	(20.1-29.5)	22.4	(16.7-28.2)	19.3	(14.2-24.4)	23.1	(11.5-34.7)	29.6	(17.3-41.9)	21.2	(7.0-35.4)	20.6	(16.3-24.9)	29.4	(25.8-33.0)	41.0	(25.4-56.7)
Daily	11.8	(8.2-15.3)	11.2	(6.9-15.6)	9.4	(5.7-13.2)	13.5	(4.1-22.8)	9.3	(1.5-17.1)	24.2	(9.4-39.1)	17.0	(13.0-21.1)	9.2	(6.9-11.5)	30.8	(16.1-45.5)
----- Age 50 years -----																		
Women																		
	(n 628)	(n 1,627)	(n 1,274)	(n 293)	(n 100)	(n 51)	(n 1,306)	(n 2,056)	(n 60)									
Any use	19.8	(16.6-22.9)	12.9	(11.3-14.5)	13.0	(11.1-14.8)	11.3	(7.6-14.9)	21.0	(13.0-29.0)	19.6	(8.6-30.6)	14.9	(12.9-16.8)	14.1	(12.6-15.6)	41.7	(29.1-54.3)
Frequency of use																		
None	80.3	(77.1-83.4)	87.1	(85.5-88.7)	87.1	(85.2-88.9)	88.7	(85.1-92.4)	79.0	(71.0-87.0)	80.4	(69.4-91.4)	85.2	(83.2-87.1)	85.9	(84.4-87.4)	58.3	(45.8-70.9)
> Daily	14.7	(11.9-17.4)	10.0	(8.5-11.4)	10.2	(8.5-11.9)	7.2	(4.2-10.1)	16.0	(8.8-23.2)	15.7	(5.6-25.8)	9.8	(8.2-11.4)	12.3	(10.8-13.7)	28.3	(16.8-39.8)
Daily	5.1	(3.4-6.8)	3.0	(2.1-3.8)	2.8	(1.9-3.7)	4.1	(1.8-6.4)	5.0	(0.7-9.3)	3.9	(-1.5-9.3)	5.1	(3.9-6.2)	1.9	(1.3-2.4)	13.3	(4.7-22.0)
----- Men -----																		
	(n 512)	(n 616)	(n 502)	(n 152)	(n 155)	(n 40)	(n 920)	(n 1,553)	(n 71)									


	----- Conditions/Diagnoses in prior year -----				----- Behavioral Health Screens -----													
	Tobacco use	Major Depression	Anxiety	Serious Mental Illness	Alcohol use disorder	Other drug use disorder	Depression (PHQ2)	Unhealthy alcohol use	Illicit drug use/Rx misuse									
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI								
Any use	27.3	(23.5–31.2)	18.3	(15.3–21.4)	19.5	(16.1–23.0)	19.1	(12.8–25.4)	23.9	(17.1–30.6)	30.0	(15.6–44.4)	20.5	(17.9–23.2)	24.0	(21.9–26.1)	50.7	(39.0–62.4)
Frequency of use																		
None	72.7	(68.8–76.5)	81.7	(78.6–84.7)	80.5	(77.0–84.0)	80.9	(74.7–87.2)	76.1	(69.4–82.9)	70.0	(55.6–84.4)	79.5	(76.8–82.1)	76.0	(73.9–78.1)	49.3	(37.6–61.0)
> Daily	21.1	(17.6–24.6)	14.8	(12.0–17.6)	15.5	(12.4–18.7)	14.5	(8.9–20.1)	19.4	(13.1–25.6)	25.0	(11.4–38.6)	13.3	(11.1–15.5)	20.2	(18.2–22.2)	36.6	(25.3–47.9)
Daily	6.3	(4.2–8.4)	3.6	(2.1–5.0)	4.0	(2.3–5.7)	4.6	(1.3–8.0)	4.5	(1.2–7.8)	5.0	(–1.8–11.8)	7.3	(5.6–9.0)	3.8	(2.9–4.8)	14.1	(5.9–22.2)

## Appendix B. Among young patients 18–29 years old with a documented condition, diagnosis or behavioral health screen, the prevalence of past-year cannabis use

*Note.* Any use is the summed total of <monthly/monthly/weekly use and daily use. Documented conditions and diagnoses were in the year prior to the clinic visit







**Figure 1.** The prevalence of past-year cannabis use among patients in age and gender subgroups (panel A) and among those with a documented condition, diagnosis or behavioral health screen (panel B)

*Note.* Any use is the summed total of <monthly/monthly/weekly use and daily use. Documented conditions and diagnoses were in the year prior to the clinic visit

**Table 1**  
**Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) criteria for a cannabis use disorder**

A problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by at least 2 of the following, occurring within a 12-month period:

- 1 Cannabis is often taken in larger amounts or over a longer period than was intended.
- 2 There is a persistent desire or unsuccessful efforts to cut down or control cannabis use
- 3 A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects
- 4 Craving, or a strong desire or urge to use cannabis
- 5 Recurrent cannabis use resulting in a failure to fulfill major role obligations at work, school, or home
- 6 Continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis
- 7 Important social, occupational, or recreational activities are given up or reduced because of cannabis use
- 8 Recurrent cannabis use in situations in which it is physically hazardous
- 9 Cannabis use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis
- 10 Tolerance, as defined by either a (1) need for markedly increased cannabis to achieve intoxication or desired effect or (2) markedly diminished effect with continued use of the same amount of cannabis
- 11 Withdrawal, as manifested by either (1) the characteristic withdrawal syndrome for cannabis or (2) cannabis is taken to relieve or avoid withdrawal symptoms

Note: The severity of a cannabis use disorder is defined as: mild (2 or 3 symptoms); moderate (4 or 5); and severe (6 or more); Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright 2013). American Psychiatric Association. All Rights Reserved.

**Table 2**

Primary care adult patients who attended pilot sites and were screened for past-year cannabis use (n 22,095)

	N	%
Gender		
Women	13,182	(59.7)
Men	8,913	(40.3)
Age categories		
18–29	2,228	(10.1)
30–49	5,194	(23.5)
50–64	6,774	(30.7)
65	7,899	(35.8)
Race/ethnicity		
Black	490	(2.2)
Hispanic	997	(4.5)
Other	1,972	(8.9)
White	17,993	(81.4)
Unknown	643	(2.9)
Tobacco use*	2,133	(9.7)
<u>Diagnoses in prior year*</u>		
Major depression	3,323	(15.0)
Anxiety disorder	2,994	(13.6)
Serious mental illness†	704	(3.2)
Alcohol use disorder	396	(1.8)
Cannabis use disorder	109	(0.5)
Other drug use disorder	200	(0.9)
<u>Behavioral health screens</u>		
Depression (PHQ-2) ‡	3,582	(16.3)
Unhealthy alcohol use‡	5,863	(26.6)
Any illicit drug use/Rx drug misuse‡	363	(1.7)

\* Assessed in the year prior to clinic visit

† Includes diagnoses for bipolar disorder, psychosis and schizophrenia

‡ Total N varies due to some patients not completing items of Behavioral Health screen: PHQ-2 (n 22,081); AUDIT-C (n 22,034); drug screen (n 21,945)

**Table 3**

Among young patients 18–29 years old with a documented condition, diagnosis or positive Behavioral Health screen, the prevalence and frequency of past-year cannabis use

	----- Conditions/Diagnoses in prior year -----				----- Behavioral Health Screens -----				
	Tobacco use % (95% CI)	Major Dep % (95% CI)	Anxiety % (95% CI)	Serious Mental Illness % (95% CI)	Alcohol Use disorder % (95% CI)	Other Drug Use Disorder % (95% CI)	Dep (PHQ-2) % (95% CI)	Unhealthy alcohol use % (95% CI)	Illicit drug use/Rx drug misuse % (95% CI)
	<b>WOMEN 18–29 years</b>								
Any use	(n 179)	(n 243)	(n 264)	(n 58)	(n 24)	(n 28)	(n 329)	(n 524)	(n 79)
53.6 (46.3–61.0)	40.3 (34.1–46.5)	37.1 (31.3–43.0)	39.7 (27.0–52.4)	58.3 (38.2–78.5)	57.1 (38.5–75.8)	47.7 (42.3–53.1)	49.8 (45.5–54.1)	72.2 (62.2–82.1)	
Frequency of use									
None	46.4 (39.0–53.7)	59.7 (53.5–65.9)	62.9 (57.0–68.7)	60.3 (47.6–73.1)	41.7 (21.5–61.8)	42.9 (24.2–61.5)	52.3 (46.9–57.7)	50.2 (45.9–54.5)	27.9 (17.9–37.8)
> Daily	35.2 (28.2–42.2)	29.2 (23.5–35.0)	29.2 (23.7–34.7)	32.8 (20.6–45.0)	37.5 (17.7–57.3)	39.3 (20.9–57.7)	32.5 (27.5–37.6)	40.7 (36.4–44.9)	51.9 (40.8–63.0)
Daily	18.4 (12.7–24.1)	11.1 (7.2–15.1)	8.0 (4.7–11.2)	6.9 (0.3–13.5)	20.8 (4.2–37.4)	17.9 (3.4–32.3)	15.2 (11.3–19.1)	9.2 (6.7–11.6)	20.3 (11.3–29.2)
	<b>MEN 18–29 years</b>								
Any use	(n 120)	(n 78)	(n 87)	(n 26)	(n 15)	(n 16)	(n 165)	(n 240)	(n 66)
65.8 (57.3–74.4)	52.6 (41.4–63.7)	52.9 (42.3–63.4)	46.2 (26.6–65.7)	60.0 (34.3–85.7)	81.3 (61.5–101.0)	63.0 (55.6–70.4)	65.0 (58.9–71.1)	92.4 (86.0–98.9)	
Frequency of use									
None	34.2 (25.6–42.7)	47.4 (36.3–58.6)	47.1 (36.6–57.7)	53.9 (34.3–73.4)	40.0 (14.3–65.7)	18.8 (-1.0–38.5)	37.0 (29.6–44.4)	35.0 (28.9–41.1)	7.6 (1.1–14.0)
> Daily	34.2 (25.6–42.7)	38.5 (27.6–49.4)	37.9 (27.7–48.2)	38.5 (19.4–57.6)	26.7 (3.5–49.9)	50.0 (24.7–75.3)	37.6 (30.2–45.0)	48.8 (42.4–55.1)	63.6 (51.9–75.4)
Daily	31.7 (23.3–40.0)	14.1 (6.3–21.9)	14.9 (7.4–22.5)	7.7 (-2.8–18.2)	33.3 (8.6–58.1)	31.3 (7.8–54.7)	25.5 (18.8–32.1)	16.3 (11.6–20.9)	28.8 (17.8–39.8)

Table 4

Adjusted\* odds of any and daily past-year cannabis use by patient characteristic

	<u>Any use</u>		<u>Daily use</u>	
	Adjusted OR	95% CI	Adjusted OR	95% CI
Gender				
Women <sup>†</sup>	--	--	--	--
Men	1.68	(1.55 1.83) <sup>§</sup>	1.87	(1.59 2.21) <sup>§</sup>
Age categories				
18–29	7.34	(6.42 8.40) <sup>§</sup>	4.82	(3.67 6.31) <sup>§</sup>
30–49	3.26	(2.90 3.68) <sup>§</sup>	2.75	(2.13 3.53) <sup>§</sup>
50–64	2.61	(2.33 2.93) <sup>§</sup>	1.92	(1.49 2.48) <sup>§</sup>
65 <sup>†</sup>	--	--	--	--
Race				
Black	0.68	(0.51 0.91)	0.75	(0.43 1.32)
Hispanic	0.92	(0.76 1.11)	1.09	(0.76 1.57)
Other	0.71	(0.61 0.83) <sup>§</sup>	0.70	(0.52 0.96)
White <sup>†</sup>	--	--	--	--
Unknown	1.00	(0.80 1.25)	1.34	(0.91 1.97)
Current tobacco use <sup>‡</sup>	2.00	(1.79 2.23) <sup>§</sup>	2.92	(2.43 3.52) <sup>§</sup>
<u>Diagnoses in prior year<sup>‡</sup></u>				
Major depression	1.35	(1.20 1.52) <sup>§</sup>	1.20	(0.96 1.49)
Anxiety disorder	1.23	(1.09 1.38)	1.23	(0.98 1.55)
Serious mental illness	1.45	(1.18 1.79) <sup>§</sup>	1.51	(1.05 2.17)
Alcohol use disorder	0.89	(0.69 1.16)	0.94	(0.61 1.46)
Other drug use disorder	1.41	(0.98 2.04)	0.94	(0.54 1.62)
<u>Behavioral health screens</u>				
Depression (PHQ-2) <sup>*</sup>	1.77	(1.61 1.96) <sup>§</sup>	3.89	(3.28 4.60) <sup>§</sup>
Unhealthy alcohol use	2.76	(2.54 3.00) <sup>§</sup>	1.47	(1.24 1.74) <sup>§</sup>
Any illicit drug use/Rx drug misuse	5.19	(4.05 6.66) <sup>§</sup>	2.86	(2.08 3.95) <sup>§</sup>

	<u>Any use</u>		<u>Daily use</u>	
	Adjusted OR	95% CI	Adjusted OR	95% CI
constant	0.03	(0.03 0.03) <sup>§</sup>	0.00	(0.00 0.01) <sup>§</sup>

\* Adjusted for all patient characteristics: gender, age, race, ethnicity, current tobacco use, diagnoses and behavioral health screens;

<sup>†</sup> Referent group;

<sup>‡</sup> Assessed in the year prior to clinic visit;

<sup>§</sup> p-value <0.001; p-value <0.05